MétaCan
Menu
← Back to cohort
Record W4417248653 · doi:10.1371/journal.pone.0331163

Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1): Protocol of an international natural history study

2025· article· en· W4417248653 on OpenAlexaff
Karlien Mul, Kate Eichinger, Man Hung, Valeria Sansone, Cynthia Gagnon, S. H. Subramony, Richard Roxburgh, Johanna Hamel, Jeffrey Statland, Bakri Elsheikh, Christopher T. Turner, Jacinda B. Sampson, Thomas Ragole, Emma Matthews, Benedikt Schoser, Andrea Swenson, Perry B. Shieh, Ericka Greene, Masanori Takahashi, Matthew Wicklund, Jeanne Dekdebrun, Jennifer K. Raymond, Erin DeSpain, Charles A. Thornton, Nicholas E. Johnson

Bibliographic record

VenuePLoS ONE · 2025
Typearticle
Languageen
FieldNeuroscience
TopicGenetic Neurodegenerative Diseases
Canadian institutionsCentre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean
FundersSanofi GenzymeVertex PharmaceuticalsTakeda Pharmaceuticals U.S.A.PfizerU.S. Food and Drug AdministrationMyotonic Dystrophy Foundation
KeywordsMyotonic dystrophyNatural historyNatural history studyProtocol (science)MEDLINE

Abstract

fetched live from OpenAlex

BACKGROUND: Myotonic dystrophy type 1 (DM1) is an autosomal dominant inherited multi-system disorder that affects skeletal muscles but also many other organ systems. Molecular targets have been identified and targeted therapies are being developed and tested in first-in-human clinical trials. However, insufficient knowledge of the phenotypic heterogeneity and natural course of the disease, together with a lack of reliable biomarkers, complicate the design of clinical trials. METHODS: The main objectives of this study are to 1) characterize the phenotypic heterogeneity and disease progression of DM1 in a large cohort; 2) identify baseline characteristics that predict subsequent progression; 3) validate RNA biomarkers of disease severity. This is a prospective, multi-site observational study with a follow-up period of 24 months including approximately 700 adult DM1 patients. Visits will occur at baseline, and months 12 and 24. All patients will undergo strength testing, myotonia assessment, a battery of functional outcome assessments, spirometry, and complete various questionnaires and cognitive tests. Blood and urine samples will be taken at each visit for biomarker studies. A subset of 60 patients will undergo a muscle biopsy at baseline and at an additional 3-month visit. The sensitivity to disease progression and minimally clinically important differences will be determined for the various clinical outcome measures. Associations between baseline patient characteristics and the rate of disease progression will be evaluated. DISCUSSION: The results of this large international study on DM1 will contribute to optimizing clinical trial design. Both data and biological samples will be collected for future research as well. TRIAL REGISTRATION: Clinicaltrials.gov NCT03981575.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.071
metaresearch head score (Gemma)0.030
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.071
Threshold uncertainty score0.375

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0710.030
Meta-epidemiology (narrow)0.0030.001
Meta-epidemiology (broad)0.0040.003
Bibliometrics0.0030.004
Science and technology studies0.0040.003
Scholarly communication0.0020.002
Open science0.0040.003
Research integrity0.0040.004
Insufficient payload (model declined to judge)0.0140.006

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.085
GPT teacher head0.347
Teacher spread0.262 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venuePLoS ONE→Same topicGenetic Neurodegenerative Diseases→French-language works237,207→